Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Clara G. Chisari, Simona Toscano, Emanuele D’Amico, Salvatore Lo Fermo, Aurora Zanghì, Sebastiano Arena, Mario Zappia & Francesco Patti. (2019) An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 18:10, pages 925-948.
Read now
Read now
Nikolaos Grigoriadis, Michael Linnebank, Nektaria Alexandri, Sarah Muehl & Günther F. L. Hofbauer. (2016) Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opinion on Pharmacotherapy 17:15, pages 2085-2095.
Read now
Read now
Jong-Mi Lee & May H Han. (2015) Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod. Patient Preference and Adherence 9, pages 685-693.
Read now
Read now
Craig J Smith, Adam Denes, Pippa J Tyrrell & Mario Di Napoli. (2015) Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke. Expert Opinion on Investigational Drugs 24:5, pages 623-643.
Read now
Read now
Angel P Sempere & Juana Gimenez-Martinez. (2014) Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. Expert Opinion on Drug Safety 13:10, pages 1287-1289.
Read now
Read now
Articles from other publishers (24)
A. A. Garibyan, E. S. Delyagina, M. L. Antipova, E. G. Odintsova, V. E. Petrenko & I. V. Terekhova. (2023) Experimental and Theoretical Investigation of Inclusion Complexes of β-Cyclodextrin with Fingolimod. Russian Journal of Physical Chemistry A 97:3, pages 469-476.
Crossref
Crossref
Simone Dertschnig, Peter Gergely, Jürgen Finke, Urs Schanz, Ernst Holler, Udo Holtick, Gérard Socié, Michael Medinger, Jakob Passweg, Takanori Teshima, Christos Stylianou, Stephan Oehen, Dominik Heim & Christoph Bucher. (2022) Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplantation and Cellular Therapy.
Crossref
Crossref
Ramya Talanki Manjunatha, Salma Habib, Sai Lahari Sangaraju, Daniela Yepez & Xavier A Grandes. (2022) Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus.
Crossref
Crossref
Wladimir Mauhin, Abdellah Tebani, Damien Amelin, Lenaig Abily-Donval, Foudil Lamari, Jonathan London, Claire Douillard, Bertrand Dussol, Vanessa Leguy-Seguin, Esther Noel, Agathe Masseau, Didier Lacombe, Hélène Maillard, Soumeya Bekri, Olivier Lidove & Olivier Benveniste. (2022) Sphingosine-1-Phosphate Levels Are Higher in Male Patients with Non-Classic Fabry Disease. Journal of Clinical Medicine 11:5, pages 1233.
Crossref
Crossref
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron & Mary Rensel. (2020) Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines 9:1, pages 12.
Crossref
Crossref
Lucia Moiola, Paulus S. Rommer & Uwe K. Zettl. (2020) Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. Current Opinion in Neurology 33:3, pages 286-294.
Crossref
Crossref
Nadja Demitrowitz & Tjalf Ziemssen. (2020) Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. Kompass Autoimmun 2:4, pages 147-150.
Crossref
Crossref
Xiuxiang Liu, Jinjin Wu, Chenying Zhu, Jie Liu, Xiaoli Chen, Tao Zhuang, Yashu Kuang, Yanfang Wang, Hao Hu, Ping Yu, Huimin Fan, Yuzhen Zhang, Zhongmin Liu & Lin Zhang. (2019) Endothelial S1pr1 regulates pressure overload‐induced cardiac remodelling through AKT‐eNOS pathway. Journal of Cellular and Molecular Medicine 24:2, pages 2013-2026.
Crossref
Crossref
Andrew R. Clark & Michael Ohlmeyer. (2019) Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. Pharmacology & Therapeutics 201, pages 181-201.
Crossref
Crossref
Jonathan Q. Tran, Jeffrey P. Hartung, Allan D. Olson, Boaz Mendzelevski, Gregg A. Timony, Marcus F. Boehm, Robert J. Peach, Sheila Gujrathi & Paul A. Frohna. (2018) Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study. Clinical Pharmacology in Drug Development 7:3, pages 263-276.
Crossref
Crossref
Yara Dadalti Fragoso. (2017) Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurologica Belgica 117:4, pages 821-827.
Crossref
Crossref
P. Soelberg Sorensen. (2017) Safety concerns and risk management of multiple sclerosis therapies. Acta Neurologica Scandinavica 136:3, pages 168-186.
Crossref
Crossref
Frederic D. Darios, Jernej Jorgacevski, Ajda Flašker, Robert Zorec, Virginia García-Martinez, José Villanueva, Luis M. Gutiérrez, Charlotte Leese, Manjot Bal, Elena Nosyreva, Ege T. Kavalali & Bazbek Davletov. (2017) Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion. Scientific Reports 7:1.
Crossref
Crossref
Sinead O'Sullivan & Kumlesh K. Dev. (2017) Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases. Neuropharmacology 113, pages 597-607.
Crossref
Crossref
Di Fu, Yingchun Li, Jia Li, Xiaoyan Shi, Ronghui Yang, Yuan Zhong, Huihan Wang & Aijun Liao. (2016) The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. Molecular and Cellular Biochemistry 424:1-2, pages 185-193.
Crossref
Crossref
Aldo Bonaventura, Luca Liberale, Alessandra Vecchié, Matteo Casula, Federico Carbone, Franco Dallegri & Fabrizio Montecucco. (2016) Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. International Journal of Molecular Sciences 17:12, pages 1967.
Crossref
Crossref
Wohn-Jenn Leu, Sharada Prasanna Swain, She-Hung Chan, Jui-Ling Hsu, Shih-Ping Liu, Mei-Ling Chan, Chia-Chun Yu, Lih-Ching Hsu, Yen-Lin Chou, Wei-Ling Chang, Duen-Ren Hou & Jih-Hwa Guh. (2016) Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Oncotarget 7:47, pages 76995-77009.
Crossref
Crossref
Lorenzo Gaetani, Paola S. Menduno, Francesco Cometa, Maria Di Gregorio, Paola Sarchielli, Carlo Cagini, Paolo Calabresi & Massimiliano Di Filippo. (2015) Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature. Journal of Neurology 263:3, pages 422-427.
Crossref
Crossref
Vittorio Racca, Marco Di Rienzo, Rosella Cavarretta, Anastasia Toccafondi, Emanuele Vaini, Maurizio Ferratini & Marco Rovaris. (2015) Fingolimod effects on left ventricular function in multiple sclerosis. Multiple Sclerosis Journal 22:2, pages 201-211.
Crossref
Crossref
Naoko Ueda & Kyoko Saida. (2015) Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmology 15:1.
Crossref
Crossref
Adnan M. Subei & Daniel Ontaneda. (2015) Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs 29:9, pages 759-771.
Crossref
Crossref
Kathryn J. Quigley, Catherine J. Reynolds, Amelie Goudet, Eleanor J. Raynsford, Ruhena Sergeant, Andrew Quigley, Stefan Worgall, Diana Bilton, Robert Wilson, Michael R. Loebinger, Bernard Maillere, Daniel M. Altmann & Rosemary J. Boyton. (2015)
Chronic Infection by Mucoid
Pseudomonas aeruginosa
Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F
. American Journal of Respiratory and Critical Care Medicine 191:11, pages 1250-1264.
Crossref
Crossref
Yara Dadalti Fragoso, Tarso Adoni, Sidney Gomes, Marcus Vinicius Magno Goncalves, Andre Palma da Cunha Matta, Maria Fernanda Mendes & Fabio Siquineli. (2015) Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod. Headache: The Journal of Head and Face Pain 55:4, pages 578-579.
Crossref
Crossref
Laure Michel, Catherine Larochelle & Alexandre Prat. (2015) Update on treatments in multiple sclerosis. La Presse Médicale 44:4, pages e137-e151.
Crossref
Crossref